Jasper Therapeutics Inc
Research Jasper Therapeutics Inc (JSPR) on Bullrun: market cap USD 20.22M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJSPR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 20.22M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.17M
- Free cash flow-USD 68.87M
Valuation Snapshot
latest market cap is USD 20.22M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 75.80M | -USD 77.17M | n/a | -3.95 | USD 28.69M | USD 1.24M | USD 4.15M |
| FY2024 | USD 0 | -USD 71.27M | -USD 63.15M | n/a | -4.89 | USD 71.64M | USD 1.81M | USD 61.67M |
| FY2023 | n/a | -USD 64.47M | n/a | n/a | -6.18 | USD 86.89M | USD 2.79M | USD 78.44M |
| FY2022 | n/a | -USD 37.69M | n/a | n/a | -10.33 | USD 38.25M | USD 4.02M | USD 35.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 20.22M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 51.23M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 321.17M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 88.03M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 17.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 297.16M | n/a | n/a | n/a |
Company Brief
Jasper Therapeutics reported Q2 results that beat expectations despite a share price decline and is now pursuing a merger with Kira Biosciences for additional capital. Wall Street reaction remains mixed, highlighted by Evercore ISI lowering its price target to $7 amidst broader market activity in the chronic…
The company remains loss-making but posted a 29.3% year-over-year increase in net income during the trailing twelve-month period.
Investors will monitor the progress of the proposed merger with Kira Biosciences and the potential impact on valuation given analyst downgrades, while keeping an eye on clinical development timelines for its lead candidate briquilimab.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jasper Therapeutics Inc's market cap?
Jasper Therapeutics Inc's market capitalization is USD 20.22M.
What does Jasper Therapeutics Inc do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc.